FibroGen announced a royalty monetization financing with NovaQuest Capital Management that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth. NovaQuest is a strategic...
Read Story
November 08, 2022, 07:45 AM
|
Hansa Biopharma AB, (Hansa), a pioneer in enzyme technology for rare immunological conditions, has entered into an agreement with U.S.-based NovaQuest Capital Management, securing $70 million in non-dilutive financing."This transaction, which extends...
Read Story
July 21, 2022, 07:45 AM
|
Argenta Limited and NovaQuest Capital Management announced a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s...
Read Story
May 24, 2021, 06:00 AM
|